Jennifer Ann Woyach MD

Hematologic Oncology

Professor

460 W 10th AveColumbus, OH 43210
Phone+1 614-293-3196
Fax+1 614-293-4812

Dr. Woyach is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Woyach's full profile Already have an account?

Education & Training

Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2009 - 2012
Ohio State University HospitalResidency, Internal Medicine, 2005 - 2008
Ohio State University College of MedicineClass of 2005

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

OH State Medical License 2005 - 2027
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)
COMPLETED
PHASE1
Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL Start of enrollment: 2014 Jan 17
COMPLETED
PHASE2
Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia Start of enrollment: 2018 Aug 16
COMPLETED
PHASE1

Publications & Presentations

PubMed

Hodgkin lymphoma transformation in patients with chemotherapy-naïve chronic lymphocytic leukemia.
Paul J Hampel, Ying Huang, John N Allan, Seema A Bhat, David Bond
Blood Cancer Journal. 2026-09-26
Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22.
Sumithira Vasu, Nathan Denlinger, No-Joon Song, Danielle Elsberry, Qiuhong Zhao
Blood Cancer Discovery. 2026-09-03
T-cell immunosenescence limits CD19 CAR T-cell function in chronic lymphocytic leukemia.
Julia Han Noll, Devin Dersh, Jiang Yuan Li, Humza Hemani, Maya Lavorando
Blood. 2026-08-24

Journal Articles

Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia
Jennifer Woyach, MD, Cancer Discovery
Ibrutinib and Aspergillus: A Btk-Targeted Risk
Jennifer Woyach, MD, Blood

Abstracts/Posters

The Protein Kinase C Inhibitor MS-553 for the Treatment of Chronic Lymphocytic Leukemia
Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocy...
Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

MRD Testing to Guide Treatment Decisions in CLL
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Authored Content

Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic LeukemiaMarch 2020

Press Mentions

Early Results Show Pirtobrutinib Matches Ibrutinib in BTK Inhibitor-Naive CLLJanuary 8th, 2026
First-Of-Its-Kind Phase 3 Trial Shows Pirtobrutinib Is Noninferior to Ibrutinib in Treatment-Naïve CLLDecember 9th, 2025
New Therapies and Immunotherapies in Treating Blood CancersDecember 8th, 2025

Grant Support

OSU as a Network Lead Academic Participating Site for the NCI NCTNOHIO STATE UNIVERSITY2019–2032
Rationally directed therapy for CLLUNIVERSITY OF TX MD ANDERSON CAN CTR2026–2031
Targeted Therapies for Lymphoid MalignanciesOHIO STATE UNIVERSITY2013–2026
Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell MalignanciesBAYLOR COLLEGE OF MEDICINE2020–2025
Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell MalignanciesBAYLOR COLLEGE OF MEDICINE2020–2025